Department of Radiation Oncology, University of California, Irvine, Irvine, California 92697-2695.
Laboratory of Radiation Oncology, Department of Radiation Oncology. Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Radiat Res. 2020 Dec 1;194(6):636-645. doi: 10.1667/RADE-20-00067.1.
Encephalic radiation therapy delivered at a conventional dose rate (CONV, 0.1-2.0 Gy/min) elicits a variety of temporally distinct damage signatures that invariably involve persistent indications of neuroinflammation. Past work has shown an involvement of both the innate and adaptive immune systems in modulating the central nervous system (CNS) radiation injury response, where elevations in astrogliosis, microgliosis and cytokine signaling define a complex pattern of normal tissue toxicities that never completely resolve. These side effects constitute a major limitation in the management of CNS malignancies in both adult and pediatric patients. The advent of a novel ultra-high dose-rate irradiation modality termed FLASH radiotherapy (FLASH-RT, instantaneous dose rates ≥106 Gy/s; 10 Gy delivered in 1-10 pulses of 1.8 µs) has been reported to minimize a range of normal tissue toxicities typically concurrent with CONV exposures, an effect that has been coined the "FLASH effect." Since the FLASH effect has now been found to significantly limit persistent inflammatory signatures in the brain, we sought to further elucidate whether changes in astrogliosis might account for the differential dose-rate response of the irradiated brain. Here we report that markers selected for activated astrogliosis and immune signaling in the brain (glial fibrillary acidic protein, GFAP; toll-like receptor 4, TLR4) are expressed at reduced levels after FLASH irradiation compared to CONV-irradiated animals. Interestingly, while FLASH-RT did not induce astrogliosis and TLR4, the expression level of complement C1q and C3 were found to be elevated in both FLASH and CONV irradiation modalities compared to the control. Although functional outcomes in the CNS remain to be cross-validated in response to the specific changes in protein expression reported, the data provide compelling evidence that distinguishes the dose-rate response of normal tissue injury in the irradiated brain.
常规剂量率(CONV,0.1-2.0Gy/min)下的颅脑放射治疗会引发多种具有时间差异的损伤特征,这些损伤特征始终涉及持续存在的神经炎症迹象。过去的研究表明,固有免疫和适应性免疫系统都参与了调节中枢神经系统(CNS)辐射损伤反应,其中星形胶质细胞增生、小胶质细胞增生和细胞因子信号的升高定义了一种正常组织毒性的复杂模式,这种毒性永远不会完全消除。这些副作用构成了成人和儿童患者中枢神经系统恶性肿瘤治疗的主要限制。一种新型超高剂量率照射方式,即 FLASH 放射治疗(FLASH-RT,瞬时剂量率≥106Gy/s;10Gy 在 1-10 个 1.8µs 的脉冲中传递)的出现,据报道可以最大限度地减少通常与 CONV 照射同时发生的一系列正常组织毒性,这种效应被称为“FLASH 效应”。由于已经发现 FLASH 效应显著限制了大脑中持续的炎症特征,我们试图进一步阐明星形胶质细胞增生的变化是否可以解释辐照大脑的不同剂量率反应。在这里,我们报告说,在大脑中选择用于激活星形胶质细胞增生和免疫信号的标志物(胶质纤维酸性蛋白,GFAP; toll 样受体 4,TLR4)在 FLASH 照射后表达水平低于 CONV 照射的动物。有趣的是,虽然 FLASH-RT 没有诱导星形胶质细胞增生和 TLR4,但在 FLASH 和 CONV 照射方式下,补体 C1q 和 C3 的表达水平都比对照组升高。尽管中枢神经系统的功能结果仍有待交叉验证,但报告的蛋白质表达特定变化的反应,数据提供了令人信服的证据,区分了辐照大脑正常组织损伤的剂量率反应。